Advanced surgical technology, certified technician network and OEM partnerships position Agiliti as a leading, nationwide partner in prostate cancer diagnosis and treatment

Agiliti, a leading manufacturer and provider of medical device solutions to the U.S. healthcare industry, has expanded its oncology offerings to physicians and hospitals, providing greater value and access to focal therapy services for diagnosing and treating prostate cancer.

“There are approximately 313,000 new prostate cancer cases every year in the U.S., and innovative technologies like HIFU and other focal therapies are an important component of modern care,” explained Casey Branham, General Manager of Surgical Technology Services at Agiliti. “Agiliti is a leading provider of on-demand surgical laser technology and technician services in the U.S., and we are committed to offering our customers and their patients a broad range of surgical support options designed to drive safe, efficient and effective outcomes in the OR.”

HIFU and other focal therapy technologies provide physicians, urologists and oncologists with the ability to precisely target and ablate (destroy) the cancerous tissue while minimizing damage to surrounding healthy tissue. This has been shown to help speed recovery and lower the risk of complications, such as urinary incontinence and erectile dysfunction, as compared to other treatment options for prostate cancer.

With a nationwide footprint and range of innovative treatment options, Agiliti is a leading provider of focal therapy technologies. An expanded fleet of technology along with the most experienced certified technicians means Agiliti can significantly improve the availability and speed at which customers can access focal therapy technology and offer comprehensive prostate cancer care services for hospitals – from diagnosis to treatment. In addition, Agiliti provides access to a range of complementary solutions for healthcare providers to start a focal therapy program in their practice.

Agiliti holds partnerships with leading technology providers across the country, including:

• BotImage AI: Their ProstatID® platform is the only FDA-approved AI software for prostate cancer screening and advanced prostate cancer detection and diagnosis.
• Koelis: A leading MRI fusion guidance manufacturer with their flagship product, Trinity®, widely considered the most versatile system for use in biopsy and therapy, and the most accurate and efficient due to its proprietary 3D Ultrasound and Organ Based Tracking® technology.
• Sonablate: This exclusive partnership brings the nation’s premiere HIFU system to all Agiliti customers nationwide.
• Varian, a Siemens Healthineers Company: Partner for cryotherapy and microwave ablation products, providing a multiple ablation technology treatment portfolio.

“Oncology has entered a more personalized and targeted phase of care – technology like ablative therapies and HIFU are quickly becoming critical components of modern cancer treatment,” said Dr. Eugene Cone, M.D., Urologic Oncologist. “Healthcare institutions and physicians that don’t integrate these advance treatment options into their service lines risk falling behind.”

To learn more about the full range of oncology offerings from Agiliti, including access to the latest technologies and talent, visit our Surgical Technology page at agilitihealth.com.

About Agiliti

Agiliti is a leading manufacturer and service provider of essential medical and surgical equipment to the U.S. healthcare industry. Agiliti serves more than 10,000 national, regional and local acute care and alternate site providers across the U.S. For more than eight decades, Agiliti has delivered medical device management and service solutions that help healthcare providers reduce costs, increase operating efficiencies and support optimal patient outcomes. To learn more visit agilitihealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250923651371/en/

“Healthcare institutions and physicians that don’t integrate these advance treatment options into their service lines risk falling behind.”